MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.
Under the collaboration, Annovis will use Weave for drafting, reviewing and managing the NDA documents as the Company heads toward a 6-month top-line data readout from the pivotal Phase 3 AD trial – the data that will form the basis of the submission. Annovis’ regulatory and clinical teams will retain full responsibility for content, verification and final approval of every document submitted to the U.S. Food and Drug Administration (FDA).
“Our goal is to have most of the NDA ready before the data readout, so the path from the top-line results to filing is as short as possible,” said Eve Damiano, Senior VP, Regulatory Operations at Annovis. “Weave will let our regulatory team spend time on scientific judgment and strategy while providing essential assistance on assembling documents in a faster and more organized way. That is a meaningful advantage as we prepare a submission for an investigational therapy we believe has the potential to help millions of patients still waiting for a treatment that can change their lives.”
The collaboration follows the completion of enrollment in Annovis’ pivotal Phase 3 AD study (NCT06709014), which enrolled 862 biomarker-confirmed patients, exceeding the original target of 760. The Company aims to reach the database lock for the 6-month treatment period in December 2026, followed by the top-line symptomatic data announcement in March 2027.
“Annovis is exactly the kind of company our platform was built for – a team with deep scientific expertise, ambitious timelines, and a vision for the future of AI-driven drug development,” said Brandon Rice, CEO and co-founder of Weave Bio. “NDA submissions are not just about writing documents, they are about weaving years of scientific knowledge into a coherent, traceable narrative. We are privileged to help Annovis do that for a disease area that still has no effective treatment.”
Annovis and Weave Bio have aligned their approach around the FDA’s guidance on the use of AI to support regulatory decision-making, issued in January 2025, keeping regulatory professionals in control of AI-assisted drafting, extraction, traceability and review.
About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com
Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com
From its largest business accelerator cohort to-date to strengthening AI oversight policies, Fiverr is showcasing its expanded efforts, impact, and support for entrepreneurs and AI governance
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Fiverr International Ltd. (NYSE: FVRR) released its 2025 Impact Report, highlighting how the company is helping shape a more inclusive, responsible and sustainable future of work. As artificial intelligence continues to transform how work is created and delivered, the report outlines how Fiverr is expanding access to economic opportunity, strengthening marketplace trust and governance, investing in its global community, and reducing its environmental impact.
“The world of work is changing faster than ever, driven by advances in AI and new technologies,” said Micha Kaufman, founder and CEO of Fiverr. “At Fiverr, we believe technology should expand human potential, not limit it. Throughout 2025, we continued to invest in the freelancers, entrepreneurs and communities that power our ecosystem, while strengthening the governance, trust and responsible innovation needed to help people succeed in the future of work.”
Highlights from the 2025 Impact Report include:
Creating Fair Economic and Social Opportunities
Supported more than 50 nonprofit and community organizations through the Colors Foundation, with $1.2M in donations and over 480 employees contributing 2,900 volunteer hours
Hosted 125 community events with 13.9K attendees
Joined Pledge 1% which reinforces Fiverr’s commitment to community investment and social impact
In 2025, Fiverr launched its fifth Future Collective cohort, supporting 15 entrepreneurs, before expanding the program to its largest cohort to date in 2026 with 22 participating founders
Celebrated our fourth annual International Freelancer Day to honor and celebrate freelancers across the globe with a campaign featuring members of our community on digital billboards in Times Square
Participated in the March of the Living, where we joined high-tech delegation leaders and employees in an international march in Poland
Published the annual Freelance Economic Impact Report, Fiverr’s Next Gen of Work Report and the Business Trends Index 2026 providing data-driven insights into workforce trends, the future of freelancing and businesses’ growing adoption of AI
Marketplace Integrity and Ethics
Zero data breaches reported globally
Maintained ISO 27001, ISO 27701, and PCI DSS certifications
Strengthened marketplace governance, compliance, and AI oversight practices through cross-functional policy and steering committees
Hosted Cybersecurity Week to boost internal awareness
Empowering Our People
77% of employees participated in the 2025 annual engagement survey
Achieved a 78% favorable score in the 2025 engagement survey
49.8% of global team identified as female, 46% of global management team identified as female and 29% female representation on the board of directors
Climate Change
Reduced 2025 Scope 1 and 2 emissions by 28% as compared to 2024
In 2025, 60% of the electricity consumed at our HQ was sourced from renewable energy
Expanded recycling streams, increased recycling infrastructure, and promoted responsible waste disposal through company-wide awareness campaigns
For more details about these and other initiatives, please find the full report here.
About Fiverr Fiverr’s mission is to transform the way the world creates and works together. We’re shaping the future of work with the world’s leading open platform, seamlessly connecting top talent and cutting-edge technology with businesses around the globe. From expert freelancers in over 750 skilled categories to best-in-class GenAI models and agents, Fiverr provides the most advanced and comprehensive talent and tools for digital services – helping businesses get mission-critical projects done fast and cost-effectively.
From small businesses to Fortune 500 companies, millions trust Fiverr for projects in software and AI development, digital marketing, finance, business consulting, video animation, music, architecture, and more.
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.
“We are delighted to welcome Nancy to our board,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “As an experienced board director and C-suite executive who has both led and advised global Fortune 500 companies, Nancy brings deep expertise in corporate governance, global finance, enterprise risk management, and large-scale transformation. Her strategic and operational acumen, along with experience spearheading financial and governance frameworks to support corporate objectives, will bring significant value to Tempest.”
Ms. Freda-Smith is a seasoned public company board director and senior finance and audit executive with more than 30 years of experience advancing corporate governance, financial reporting, enterprise risk management, and regulatory compliance across global organizations. She most recently served as Chief Audit and Risk Officer at Ralph Lauren where she led internal audit, Sarbanes-Oxley Act compliance, enterprise risk management, asset protection, cybersecurity resilience, and global control transformation across operations spanning over 30 countries and more than $7 billion in revenue. Previously, she served as an Independent Director and Audit Committee Member of Chuy’s Holdings, providing oversight during its acquisition by Darden Restaurants, including M&A execution, cybersecurity response, SEC disclosure, and financial risk management. Earlier, as Managing Director at Deloitte & Touche LLP, Ms. Freda-Smith advised Fortune 500 companies on SEC reporting, capital markets transactions, complex U.S. GAAP and IFRS matters, and audit quality. Her clients included companies across the pharmaceutical and life sciences sector among other industries. She is a Certified Public Accountant and Certified Fraud Examiner. Ms. Freda-Smith also holds a Bachelor of Science in Accounting from Boston College.
Ms. Freda-Smith added, “Tempest’s science and its differentiated approach to in vivo CAR-T are genuinely compelling, and I’m encouraged by the company’s efforts to broaden its pipeline and strategic partnerships, creating additional avenues for value creation. I look forward to bringing rigorous financial oversight and governance discipline to the board as Tempest works to execute on this next chapter, and to supporting the team in pursuit of that potential.”
About Tempest Therapeutics
Tempest is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest’s lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: the potential applicability of Tempest’s platform and product candidates across autoimmune and oncology indications; and Tempest’s ability to achieve its operational plans. All forward-looking statements in this press release are based on Tempest’s current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest’s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest.
Investor Contacts:
Sylvia Wheeler Wheelhouse Life Science Advisors swheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com
New HO3, HO5, and HO6 products bring more choice and coverage options to South Carolina’s coastal market
TAMPA, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — Slide Insurance Holdings, Inc. (“Slide” or the “Company”) (NASDAQ: SLDE) today announced an expanded suite of property insurance products available statewide in South Carolina, with a focus on bringing more choice and admitted capacity to the coast.
The expanded offerings, offered through Slide Specialty Insurance Company, include a new HO5 product designed for higher-value homes, plus new HO3 homeowners and HO6 condo products. All three feature expanded coverage options, additional discounts, and highly competitive rates, giving South Carolina homeowners greater flexibility to find coverage that fits their needs and budget.
South Carolina’s rapidly growing coastal communities need more home insurance options, particularly for larger and higher-value homes, where finding coverage can be challenging. Areas like Horry County, home to the Myrtle Beach area, have grown by more than 20% since 2020, according to U.S. Census Bureau population estimates, illustrating the growing demand for committed coastal capacity.
“Coastal property insurance is where Slide has a distinct advantage,” said Bruce Lucas, Chairman and Chief Executive Officer of Slide. “We’re deepening our commitment to South Carolina at a time when the coastal market is growing, and homeowners need more options. We have the underwriting technology, financial strength and experience to deploy capacity where we see attractive opportunities while maintaining a disciplined approach to risk.”
Slide has served South Carolina homeowners since 2022. Its product expansion in South Carolina advances the company’s strategy of disciplined growth and geographic diversification in property insurance markets where its underwriting and catastrophe risk management capabilities provide a competitive advantage.
South Carolina homeowners who are interested in learning more about Slide’s new coverage options can visit www.slideinsurance.com/sc.
Forward-Looking Statements
Statements in this press release that are not historical facts are forward-looking statements that are subject to certain risks and uncertainties that could cause actual events and results to differ materially from those discussed herein. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “aim,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology and relate, without limitation, to the Company’s beliefs and expectations regarding the Company’s projections of future financial performance including net margins and its share repurchase program and its ability to increase return on equity and build long-term value for shareholders. These statements are only predictions based on Slide’s current expectations and projections about future events and are not guarantees of actual results, level of activity, performance or achievements. Although Slide believes the expectations reflected in the forward-looking statements are based on reasonable assumptions, there are important factors that could cause the Company’s actual results, level of activity, performance or achievements to differ materially from those anticipated in any forward-looking statements, including, among others, our limited operating history; the success of the Company’s underwriting and profitability initiatives; inflation and other changes in economic conditions (including changes in interest rates and financial and real estate markets), including changes that may impact demand for our products and our operations; lack of effectiveness of exclusions and loss limitation methods in the insurance policies we assume or write; inherent uncertainty of our models and our reliance on such models as a tool to evaluate risk; the impact of macroeconomic conditions, including declining consumer confidence, inflation, high unemployment and the threat of recession; the impact of new federal and state regulations that affect the property and casualty insurance market and our failure to meet increased regulatory requirements, including minimum capital and surplus requirements; the cost of reinsurance, the collectability of reinsurance and our ability to obtain reinsurance coverage on terms and at a cost acceptable to us; assessments charged by various governmental agencies; pricing competition and other initiatives by competitors; our ability to obtain regulatory approval for requested rate changes, and the timing thereof; legislative and regulatory developments; the outcome of litigation pending against us, including the terms of any settlements; risks related to the nature of our business; performance of our investment portfolio; the adequacy of our liability for losses and loss adjustment expense; ratings by industry services; catastrophe losses; reliance on key personnel; weather conditions (including the severity and frequency of storms, hurricanes, tornadoes, wildfires and hail); acts of war and terrorist activities; court decisions and trends in litigation; and other matters described from time to time by us in our filings with the Securities and Exchange Commission. Any forward-looking statement made by Slide in this press release speaks only as of the date on which it is made. Slide undertakes no obligation to update any forward-looking statement, whether as a result of new information, actual results, revised expectations or otherwise, except as may be required by law.
About Slide
Slide Insurance Holdings, Inc. (NASDAQ: SLDE) is a Tampa-based specialty property insurer built for coastal and catastrophe-prone markets. Slide combines advanced technology with deep insurance expertise to maintain a disciplined approach to risk, bring additional capacity to the markets it serves along with its network of more than 5,000 independent agents, and provide a dependable, streamlined insurance experience to its policyholders. Slide ranks among the 25 largest U.S. homeowners insurance groups by direct written premium, according to the National Association of Insurance Commissioners (NAIC). For more information, visit slideinsurance.com.
Contacts
Investors ir@slideinsurance.com
Media Rachel Carr Chief Marketing Officer press@slideinsurance.com
Lille, Sept. 23, 2026 (GLOBE NEWSWIRE) — Top Wealth Group Holding Limited (NASDAQ: TWG)(“Top Wealth” or the “Company”), a leading supplier of premium sturgeon caviar and fine wine products, today announced a positive profit alert for the current financial year ending December 31, 2026.
The Company expects net profit attributable to ordinary shareholders for the current financial year to record an increase of no less than 100% compared to the previous financial year.
Key drivers of the expected profit growth include:
Extensive corporate marketing of the Company’s position of a reputable regional supplier of premium wine and caviar, driving significant revenue growth.
While engaging in long term sustainable growth in upstream vertical integration and acquisitions, the Company succeeded in selling its precious inventory of fine wines in the premium market to loyal clients and new clients. These sales not only resulting in increase in revenue but also maintaining a good gross margin.
Enhanced operational efficiency and further realization of economies of scale.
As the Company is undergoing a strategic upward integration of its caviar business, the present year’s revenue contribution derived mainly from the premium wine section. The Company expects caviar and wine sectors will achieve more balanced growth in the future years.
The Company cautions that the above figures are preliminary estimates based on currently available information. Actual results may differ materially from these estimates due to market conditions and operational factors. The Company expects to disclose its audited full-year financial results in accordance with applicable Nasdaq rules and SEC requirements following the completion of the fiscal year.
About Top Wealth Group Holding Limited
Top Wealth Group Holding Limited is a holding company incorporated in the Cayman Islands, with all operations carried out through its operating subsidiary in Hong Kong, Top Wealth Group (International) Limited. The Company specializes in supplying premium-class sturgeon caviar, and its caviar and caviar products are endorsed with the Convention on International Trade in Endangered Species of Wild Fauna and Flora (“CITES”) permits. The Company supplies caviar to customers under customer brand labels (i.e. private labeling), and also sells under its own brand, “Imperial Cristal Caviar,” which has continuously achieved significant sales growth since its launch.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in verbal statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.
For more information, please contact:
Top Wealth Group Holding Limited Investor Relations Email: ir@topwealth.cc
MONTRÉAL, Sept. 23, 2026 (GLOBE NEWSWIRE) — Saputo Inc. (TSX: SAP) (“we”, “Saputo” or the “Company”) today announced an evolution of its organizational structure designed to strengthen the Company’s ability to execute its strategic priorities, enhance commercial execution within its ingredient business, accelerate enterprise transformation, and support continued expansion of its ingredients platform.
The changes reflect Saputo’s ongoing commitment to evolving its business to meet changing customer, consumer, and market needs while enhancing organizational agility and execution.
“As Saputo continues to evolve its portfolio and invest in growth opportunities, it is important that our organizational structure evolves alongside our business,” said Carl Colizza, President and Chief Executive Officer. “These changes are intended to increase organizational focus, strengthen accountability, and improve execution across key strategic priorities. This is about ensuring we have the right structure to support our future ambitions and create sustainable value for our stakeholders.”
New Ingredients Division
As demand for higher-value dairy ingredients continues to grow globally, Saputo is creating a dedicated Ingredients Division to accelerate innovation, strengthen commercial focus, and expand opportunities across global markets.
Steve Douglas has been appointed President and Chief Operating Officer, Ingredients, where he will be responsible for leading the division’s commercial, operational, innovation, and growth initiatives. Mr. Douglas will also remain President and Chief Operating Officer, Dairy Division (UK), until the completion of the previously announced sale of the Dairy Division (UK).
Enterprise Transformation
To support the Company’s continued evolution and accelerate the adoption of new technologies and ways of working, Saputo has created the role of Chief Enterprise Transformation Officer, to be led by Haig Poutchigian.
In this newly created role, Mr. Poutchigian will lead the integration of our business administration and operational finance, as well as information technology teams into a single enterprise services model.
The new structure is intended to improve consistency, visibility, and scalability across the enterprise. By bringing these capabilities together, Saputo expects to streamline processes, reduce complexity, improve coordination, and accelerate execution, while supporting productivity, automation, and data-driven decision-making across the enterprise.
Canadian Division
As part of its organizational evolution, Dave Paradis has been appointed President and Chief Operating Officer, Dairy Division (Canada). In this role, Mr. Paradis will lead Saputo’s Canadian operations, with a focus on advancing the division’s strategic priorities, strengthening commercial execution, enhancing customer partnerships, and driving operational excellence across the business.
Supporting the Next Phase of Growth
This organizational evolution reinforces several priorities that Saputo has communicated over recent years, including:
Expanding value-added dairy and high-protein ingredients capabilities.
Leveraging digital and AI-enabled technologies.
Simplifying processes and improving execution.
Supporting sustainable growth and value creation.
These organizational changes do not alter Saputo’s strategic priorities. Rather, they are intended to enhance focus, accountability, and execution across the business.
“Throughout our history, Saputo has continually evolved to meet the changing needs of our customers, consumers, and markets,” added Mr. Colizza. “These changes represent the next step in that evolution and will help ensure we remain well positioned to compete, grow, and create value in the years ahead.”
About Saputo Saputo, one of the top ten dairy processors in the world, produces, markets, and distributes a wide array of dairy products of the utmost quality, including cheese, fluid milk, extended shelf-life milk and cream products, cultured products, and dairy ingredients. Saputo is a leading cheese manufacturer and fluid milk and cream processor in Canada, and a leading dairy processor in Australia. In the USA, Saputo is a leading cheese producer and extended shelf-life and cultured dairy products manufacturer. Until completion of the previously announced divestiture, , Saputo remains the leading manufacturer of branded cheese and dairy spreads in the United Kingdom. In addition to its dairy portfolio, Saputo produces, markets, and distributes a range of dairy alternative products. Saputo products are sold in several countries under market-leading brands, as well as private label brands. Saputo Inc. is a publicly traded company, and its shares are listed on the Toronto Stock Exchange under the symbol “SAP”. Follow Saputo’s activities at Saputo.com or via Facebook, Instagram, and LinkedIn.
Investors and other interested parties can stay informed of Saputo’s latest news and financial disclosures by subscribing to email alerts on the Company’s website at Saputo.com.
Investor Inquiries Nicholas Estrela Senior Director, Investor Relations 1-514-328-3117
Media Inquiries 1-514-328-3141 / 1-866-648-5902 media@saputo.com
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This news release contains statements which are forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, statements with respect to our objectives, outlook, business projects, strategies, beliefs, expectations, targets, commitments, goals, ambitions and strategic plans including our ability to achieve these targets, commitments, goals, ambitions, strategic plans, and statements other than historical facts. The words “may”, “could”, “should”, “will”, “would”, “believe”, “plan”, “expect”, “intend”, “anticipate”, “estimate”, “foresee”, “objective”, “continue”, “propose”, “aim”, “commit”, “assume”, “forecast”, “predict”, “seek”, “project”, “potential”, “goal”, “target”, or “pledge”, or the negative of these terms or variations of them, the use of conditional or future tense or words and expressions of similar nature, are intended to identify forward-looking statements. All statements other than statements of historical fact included in this news release may constitute forward-looking statements within the meaning of applicable securities laws.
By their nature, forward-looking statements are subject to inherent risks and uncertainties. Actual results could differ materially from those stated, implied, or projected in such forward-looking statements. As a result, we cannot guarantee that any forward-looking statements will materialize, and we warn readers that these forward-looking statements are not statements of historical fact or guarantees of future performance in any way. Assumptions, expectations, and estimates made in the preparation of forward-looking statements and risks and uncertainties that could cause actual results to differ materially from current expectations are discussed in our materials filed with the Canadian securities regulatory authorities from time to time, including the “Risks and Uncertainties” section of the Management’s Discussion and Analysis dated June 4, 2026, available on SEDAR+ under the Company’s profile at www.sedarplus.ca.
Forward-looking statements are based on Management’s current estimates, expectations and assumptions. Management believes that these estimates, expectations, and assumptions are reasonable as of the date hereof, and are inherently subject to significant business, economic, competitive, and other uncertainties and contingencies regarding future events, and are accordingly subject to changes after such date. Forward-looking statements are intended to provide shareholders with information regarding Saputo, including our assessment of future financial plans, and may not be appropriate for other purposes. Undue importance should not be placed on forward-looking statements, and the information contained in such forward-looking statements should not be relied upon as of any other date.
Unless otherwise indicated by Saputo, forward-looking statements in this news release describe our estimates, expectations and assumptions as of the date hereof, and, accordingly, are subject to change after that date. Except as required under applicable securities legislation, Saputo does not undertake to update or revise forward-looking statements, whether written or verbal, that may be made from time to time by itself or on our behalf, whether as a result of new information, future events, or otherwise. All forward-looking statements contained herein are expressly qualified by this cautionary statement.
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline
AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027
ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced the appointments of:
Chris Hart, PhD, Chief Data and AI Officer – Dr. Hart most recently served as Vice President of Data Science and AI/ML at Eli Lilly and Company.
Thomas Wolf, PhD, Board of Directors as strategic AI advisor – Dr. Wolf is co-founder and Chief Science Officer of Hugging Face, which Nvidia has recently agreed to acquire.
“I am thrilled to welcome Chris to ProQR’s management team and Thomas to the Board of Directors as strategic advisor. Together, they bring complementary and highly relevant expertise that will help us further integrate AI into drug discovery and development as we work to deliver more and better medicines to patients faster,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “Chris brings more than 15 years of experience applying AI and machine learning to oligonucleotide therapeutics, most recently at Eli Lilly, while Thomas brings frontier AI experience from co-founding and building Hugging Face, a leading open-source AI platform. Their expertise comes at an important time for our RNA editing pipeline, with AX-0811, our first program identified through ProQR’s AI-enabled discovery process to enter clinical development, and the second, AX-2911, expected to follow in the coming months.”
Chris Hart, PhD, most recently served as Vice President of Data Science and AI/ML in the Genetic Medicines team at Eli Lilly and Company. He brings more than two decades of experience in computational biology, genomics, AI, and oligonucleotide drug development, including more than 15 years focused on AI/ML-driven optimization of oligonucleotide therapeutics. Hart was previously founding CEO of Creyon Bio, where he applied AI and machine learning to oligonucleotide drug discovery. Before Creyon, he spent seven years at Ionis Pharmaceuticals, where he built and led the company’s functional genomics group. He holds a PhD from the California Institute of Technology and completed postdoctoral training at Yale University.
As Chief Data and AI Officer, Hart will lead ProQR’s AI strategy and its execution across drug discovery and development. Drawing on his experience in AI-driven oligonucleotide engineering, he will connect ProQR’s proprietary data, computational models and experimental capabilities to accelerate EON design and optimization, strengthen candidate selection, and inform and optimize clinical development.
“ProQR has built a one-of-a-kind RNA editing platform that combines RNA biology with advanced AI to discover and optimize new therapies,” said Chris Hart, PhD. “I look forward to helping scale this approach and translate this platform into many new therapies for patients.”
Thomas Wolf, PhD, will join ProQR’s Board of Directors as strategic advisor on AI. Wolf is co-founder and Chief Science Officer of Hugging Face, the open-source AI platform that Nvidia recently agreed to acquire for $12.9B. At Hugging Face, he has built a widely adopted ecosystem of models, datasets, and tools that enable researchers and companies to develop and apply AI at scale. This work has made advanced AI more accessible, enabling teams to adapt models to their own data and translate research advances into practical applications. He is driving the development of Hugging Face’s robotics technologies and building collaborations with academia and industry to advance AI in scientific discovery. In his role, Dr. Wolf will advise ProQR’s Board on technology strategy and scaling AI across the Axiomer platform.
“ProQR is integrating AI into its proprietary RNA editing platform, which has the potential to address a broad range of diseases,” said Thomas Wolf, PhD. “The platform creates a unique opportunity as each program can build on insights from others, and AI is turning that collective learning into a growing advantage across disease targets. This makes drug discovery more systematic and efficient while increasing the probability of success in drug development. This is a key example of how AI contributes to improving human health.”
ProQR AI Strategy for Axiomer RNA Editing
ProQR is integrating AI across its Axiomer platform and workflows to support its core mission: discovering, developing, and delivering transformative RNA editing medicines to patients. The combination of ProQR’s platform technology and proprietary datasets uniquely positions the Company to maximize the impact of AI on drug discovery and development.
In discovery, AI and machine learning complement ProQR’s wet biology and experimental capabilities, enabling faster identification and optimization of EONs, across targets to capture the full value of the platform. AI-enabled discovery led to the discovery of AX-0811, which achieved approximately 60% editing efficiency in humanized models, around six-fold higher than the prior generation AX-0810, with improved stability. This was achieved with reduced discovery timelines from what used to take three years to approximately three months. ProQR’s partnership with Ginkgo Bioworks enables faster generation of high-quality data via their autonomous labs, leading to shorter learning cycles and better training sets for its AI model.
In development, ProQR is applying AI and advanced data capabilities to support more informed decisions on patient stratification, endpoint selection, and clinical trial design, incorporating insights from real-world data.
The appointments of Chris Hart, PhD, and Thomas Wolf, PhD, strengthen ProQR’s expertise to scale AI across discovery and development stages. The Company is building a continuous learning loop connecting target identification, hit optimization, lead selection and clinical development, with clinical insights feeding back into discovery and informing decisions across programs. The Company expects this approach will accelerate discovery and increase the probability of success across the development pipeline.
ProQR’s growing RNA editing pipeline is expected to generate up to 5 clinical data readouts over the coming 12 months across four development programs. AX-0811, the first ProQR program in clinical testing discovered through its AI-enabled discovery process drug that is on track for target engagement data from the first two cohorts in early January 2027. Additional programs, including AX-0422 for MPS I Hurler syndrome and AX-2911 for PNPLA3-associated MASH, are progressing toward the clinic. Together, these programs demonstrate the potential of ProQR’s scalable Axiomer platform across liver and central nervous system.
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is a clinical-stage company dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding the expected roles that Dr. Hart and Dr. Wolf will serve in and the expected benefits they will bring to ProQR; ProQR’s strategy and ability to integrate and scale artificial intelligence and machine learning across its discovery and development activities; the ability of AI-enabled discovery and proprietary data to accelerate the identification, optimization and selection of EONs and improve clinical development decisions; the potential benefits of ProQR’s collaboration with Ginkgo Bioworks; the continued development and advancement of the Axiomer platform and ProQR’s pipeline; the Phase 1 clinical development of AX-0811, including the anticipated timing of initial clinical data in early January 2027; the development and advancement of AX-2911 and AX-0422; the timing and number of anticipated clinical data readouts across ProQR’s development programs; and the therapeutic potential of Axiomer EONs and ProQR’s product candidates.
Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described in ProQR’s filings with the Securities and Exchange Commission, including certain sections of its most recent annual report on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities; the risk that preclinical or early clinical data may not be predictive of future results or clinical benefit; the likelihood that ProQR’s programs may not advance on the timelines currently anticipated; reliance on contract research organizations, contract manufacturers and other third parties; the ability to recruit and retain employees and consultants, including members of management and scientific advisors; the ability to integrate and realize the anticipated benefits of AI, machine learning and proprietary data in discovery and development; the unpredictability of regulatory requirements and the duration and results of regulatory review; possible safety or efficacy concerns that may emerge as additional data are generated; the possible impairment of, inability to obtain or costs to obtain intellectual property rights; the ability to secure, maintain and realize the intended benefits of collaborations and partnerships; risks related to cybersecurity and data privacy; general business, operational, financial and accounting risks; and risks related to macroeconomic conditions, market volatility, geopolitical events, international trade restrictions and other developments affecting ProQR’s business. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. ProQR assumes no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor and media contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Investor contact: Peter Kelleher LifeSci Advisors T: +1 617 430 7579 pkelleher@lifesciadvisors.com
New independent directors enhance Terra Innovatum’s technical and operational depth across nuclear safety, licensing, reactor engineering and fleet-scale execution as SOLO™ advances toward key licensing and commercialization milestones
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum”, “Terra”, or the “Company”) (NASDAQ: NKLR), a developer of advanced micro-modular nuclear reactors, today announced changes to the composition of its Board of Directors.
The changes come as Terra Innovatum advances the SOLO™ Micro-Modular Reactor through key licensing, first-of-a-kind deployment and industrialization milestones, and are intended to evolve the composition of the Board to support the Company’s transition from development to commercialization and its next phase of growth.
The Board has appointed Michael Modro, Kostadin Ivanov, and Tony Tullio as independent directors, effective September 22, 2026. They will serve until the Company’s next Annual General Meeting, at which point their appointments will be submitted for confirmation alongside the Company’s other nominees.
The directors bring complementary technical, financial, operational and commercial experience to support Terra Innovatum’s licensing, first-of-a-kind deployment, industrialization and broader SOLO™ commercialization.
Michael Modro brings extensive experience in nuclear safety, reactor technology and deterministic safety analysis. He has held senior technical and leadership roles in nuclear reactor safety and has worked extensively with the International Atomic Energy Agency and other nuclear organizations on safety assessment and regulatory frameworks.
Kostadin Ivanov is a recognized leader in nuclear engineering, with extensive experience in reactor physics, reactor design, and modeling and simulation. He is a Distinguished Professor and Head of the Department of Nuclear Engineering at North Carolina State University and previously held senior academic and research positions at Pennsylvania State University.
Tony Tullio brings decades of senior executive and financial leadership experience in complex, highly regulated global industrial businesses. He held senior leadership positions within Fiat Chrysler Automobiles, Alfa Romeo and Maserati, including serving as Chief Financial Officer of Maserati for the NAFTA region.
Michael W. Howard, Rex S. Jackson, and Peter Hastings will step down from the Terra Innovatum Board of Directors. Joanna Lohkamp will continue to serve on the Board.
To support this next phase of licensing, deployment and commercialization, the Board also intends to establish a Technology, Safety and Licensing Committee, subject to the adoption of the necessary governance documents, to provide focused Board-level oversight of matters relating to the SOLO™ technology platform, nuclear safety, licensing strategy, regulatory engagement and related technical and deployment activities, and to provide independent technical input to the Board and management team.
“On behalf of the Board, the leadership team and the Company, I would like to extend my sincere thanks to Michael, Rex and Peter for their service, strategic input and commitment to Terra Innovatum. Their contributions helped guide the early phases of our Company’s growth,” said Alessandro Petruzzi, Co-Founder and Chief Executive Officer of Terra Innovatum. “We are equally pleased to welcome Michael, Kostadin, and Tony to the Board as Terra Innovatum enters its next phase of development.”
ABOUT TERRA INNOVATUM & SOLO™
Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.
Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.
Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the intended licensing strategy for SOLO™ is designed to support timely deployment and minimize supply chain risks, with the aim of ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.
SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can be scaled to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.
This press release includes “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, opinions and projections prepared by Terra Innovatum’s management. Forward-looking statements generally relate to future events or future financial or operating performance, including pro forma and estimated financial information, and other “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). The recipient can identify forward-looking statements because they typically contain words such as “outlook,” “believes,” “expects,” “will,” “projected,” “continue,” “increase,” “may,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negatives or variations of these words or other comparable words and/or similar expressions (but the absence of these words and/or similar expressions does not mean that a statement is not forward-looking).
These forward-looking statements specifically include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expected timing for regulatory approvals and commercialization and the potential success of Terra Innovatum’s strategy and expectations. Forward-looking statements, opinions and projections are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of Terra Innovatum’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Terra Innovatum’s control. These uncertainties and risks may be known or unknown.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: changes in domestic and foreign business, market, financial, political and legal conditions; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; Terra Innovatum’s ability to manage future growth; Terra Innovatum’s ability to develop new products and services, bring them to market in a timely manner, and make enhancements to its platform; the effects of competition on Terra Innovatum’s future business; and the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries and other risks and uncertainties described under the heading “Risk Factors” in documents Terra Innovatum files from time to time with the Securities and Exchange Commission including Form 10-Q for the quarter ended June 30, 2026. If any of these risks materialize or Terra Innovatum’s assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking statements contained herein. In addition, forward-looking statements reflect Terra Innovatum’s expectations and views as of the date of this press release. Terra Innovatum anticipates that subsequent events and developments will cause its assessments to change. However, while Terra Innovatum may elect to update these forward-looking statements in the future, it specifically disclaims any obligation to do so. Accordingly, you should not place undue reliance on the forward-looking statements, which speak only as of the date they are made.
What topics will the 2026 Tire Emissions Research Conference cover? From how tire and road wear particles are generated to how they impact our environment, this year’s program spans five core scientific themes.
An independent Scientific Committee has designed a rich agenda that dives into every major aspect of tire and road wear emissions research:
Tire and road emissions generation and characterization (particulates and constituents) – How and how much do tires emit?
Environmental Distribution & Fate of tire emissions – Where do these particles and chemicals travel and persist?
Behavior and impact of tire emissions on the environment – What effects do tire emissions have on ecosystems and people?
Design Alternatives – How can tires, vehicles or materials be re-imagined to reduce emissions?
Civil engineering measures and environmental practices for mitigation of TRWP and chemicals – What road designs, runoff management or capture technologies can limit emissions?
Each theme addresses critical questions and solutions for more sustainable mobility. If your work touches on any of these areas, this conference will be an ideal platform to share insights and learn from peers. Let’s push the boundaries of what we know, together.
Cambridge, England
️ 8–10 December 2026
The Tire Emissions Research Conference is an event supported by the Tire Industry Project (TIP), part of the World Business Council for Sustainable Development.
NEW YORK, September 23, 2026 /3BL/ – The Paulson Institute, The Nature Conservancy (TNC), and World Wildlife Fund (WWF) today released Financing Nature Report 2026: A Mid-Decade Update: From Isolated Progress to Implementation at Scale, which underscores the importance of protecting biodiversity and assesses the current magnitude of the financing nature gap. Since publishing the first Financing Nature report in 2020, the financing gap has nearly doubled from $711 billion to $1.317 trillion a year. Drawing on practical knowledge from successful case studies by more than a dozen partner organizations, Financing Nature 2026 offers proven examples of how to close the financing gap and halt biodiversity loss by scaling nature-finance solutions. The report lays out more than just data points; it lays out action.
“I’ve always believed that a healthy planet is good for business, and it’s far cheaper to prevent environmental damage than to clean it up afterward,” said Henry M. Paulson, Jr., Chairman of the Paulson Institute. “Governments today spend more in a single month on subsidies that harm nature than they spend protecting it in an entire year. No other single action would unlock more capital for nature than reforming those subsidies, and none is more overdue. Where governments have gotten the incentives right, capital has begun to follow.”
Financing Nature 2026 arrives just a few weeks before COP17, the UN Biodiversity Conference, which the authors describe as a test of the world’s resolve to translate five years of pilots and proof points into widespread adoption. The research shows it’s not a lack of tools or evidence, but a lack of political will and harmful policies that leave nature and economies at risk.
“The conservation community has helped pioneer models that move real capital into conservation. These case studies are proof that we can protect nature and grow economies if we have the right people and programs in place,” said Jennifer Morris, Chief Executive Officer of The Nature Conservancy. “That means governments, businesses, investors and our partners on the ground align their climate, nature, and development plans before committing money, not after. We are not starting from zero. We are starting from a decade of evidence about what works, and this report is a call to build on it.”
The Financing Nature report presents a blueprint for scaling successful pilots into widespread implementation by aligning public incentives, policies, and private investment. The case studies show firsthand how both private and public institutions have moved the needle to protect nature.
“We no longer lack mechanisms for financing nature. We just need to deploy them at scale. And fast. Project Finance for Permanence deals, maturing carbon markets, impact investing, and other approaches offer promising ways forward,” said Carter Roberts, President & CEO of World Wildlife Fund. “This report proves these strategies work. But it also makes clear we need to deploy them at the pace and scale nature loss demands.”
Financing Nature 2026 was compiled with the help of contributing partners, including Bank of America, Conservation International with BTG Pactual, Goldman Sachs, Microsoft, Rare, Enosis Capital, International Crane Foundation and Endangered Wildlife Trust, Jocotoco, One Hundred Miles, Rare Systemiq, Temasek and The Nature Conservancy, whose case studies provided examples of projects that are working. Drawing on the solutions from those case studies, the report names five key recommendations for scaling proven nature-finance solutions and turning successful models into global practice:
Stop paying to destroy nature. Governments should recognize that some of their own policies and spending, including subsidies, tax breaks, loan guarantees, procurement, and infrastructure investment, actively drive nature loss, and should cut or redirect that money. For every dollar spent protecting nature, thirty go to destroying it. Reforming harmful subsidies is one of the biggest levers to close the gap. This should be done while continuing to strengthen environmental accountability for private investment and enforcement of environmental laws.
Treat nature as critical infrastructure, not a free input. Governments should treat nature as productive capital, an asset the whole economy runs on, and line up economic policy, public investment, and risk management behind protecting it.
Fight climate change and nature loss as one battle, not two. Governments, businesses, and investors should get their climate, nature, development, and investment plans in line with one another before the money is committed, not after.
Make nature-positive investment the easy investment. Governments and regulators should create the policy and market conditions that let nature finance grow at scale, and Multilateral Development Banks (MDBs) and Development Finance Institutions (DFIs) should use their balance sheets and tools to mobilize investment.
Scale what already works. Businesses and financial institutions should build nature into their strategy, everyday operations, lending, and investment, and scale up the approaches that have already worked.
“None of these priorities waits for perfect conditions,” Hank Paulson adds. “Each can begin now with the institutions and tools we already have, and each gets easier as the others advance. What is required now is not new knowledge but the political will and the sustained leadership to act on what we already know.”
About Paulson Institute The Paulson Institute is an independent, non-partisan organization advancing sustainable economic growth, climate and nature finance, and global economic stability. Founded by former US Treasury Secretary Henry M. Paulson, Jr., in 2011, the Institute applies economic and financial expertise to help address today’s most pressing environmental and geopolitical challenges. The Institute helps mobilize capital for natural infrastructure and biodiversity conservation, strengthen global green and nature finance standards, and work to advance economic prosperity. With a diverse, globally experienced team, the Institute convenes leaders, advises institutions, and helps provide practical solutions that support a more resilient, sustainable, and nature-positive future.
About The Nature Conservancy The Nature Conservancy is a global environmental nonprofit working to create a world where people and nature can thrive. Founded in the U.S. through grassroots action in 1951, The Nature Conservancy (TNC) has grown to become one of the most effective and wide-reaching environmental organizations in the world. Thanks to more than a million members and the dedicated efforts of our diverse staff and over 1,000 scientists, we impact conservation in 83 countries and territories: 39 by direct conservation impact and 44 through partners.
About World Wildlife Fund Founded in 1961, WWF works to help people and nature thrive. As a global conservation organization, WWF operates in more than 100 countries, partnering with communities, companies, and governments to protect wildlife, conserve vital habitats, and advance sustainable solutions. Grounded in science and driven by collaboration, WWF works to help nature by conserving biodiversity, supporting resilient communities, and addressing climate change. Nearly 1 million people in the United States and more than 5 million globally are WWF members.
